dosage form and wherein said dosage form exhibits accelerated release of the active agent.

34. The compressed solid dosage form according to claim 33 wherein the accelerated release constitutes about 90% release within a 10 minute, more particularly, a 5 minute period.

35. The compressed solid dosage form according to claim 33 wherein the additive is microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, pregelatinized starch or hydroxypropyl cellulose.

36. The compressed solid dosage form according to claim 33 wherein the additive is an acid in solid form.

37. The compressed solid dosage form according to claim 33 wherein the additive is citric acid.

38. A compressed solid dosage form comprising:

(a) an active agent comprising an effective amount of valsartan or a pharmaceutically acceptable salt thereof; and,

(b) at least one pharmaceutically acceptable additive ;

wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid dosage form, and wherein said dosage form exhibits delayed release of the active agent.

39. The solid dosage form according to claim 38 wherein the additive is hydroxypropyl methylcellulose.

40. A compressed solid dosage form comprising an active agent comprising an effective amount of valsartan or a pharmaceutically acceptable salt thereof; an effective amount of HCTZ; and, at least one pharmaceutically acceptable additive wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid dosage form and wherein said dosage form exhibits delayed release of the active agent.

41. The solid dosage form according to claim 40 wherein the additive is hydroxypropyl methylcellulose.